Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT

NCT00908557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2014-09-12

No results posted yet for this study

Summary

The principle objective of this randomised controlled trial is to assess whether an improvement in lexico-syntactic readability combined with adherence to French recommendations for good practice in writing the Information and Consent Form (ICF) given to patients participating in clinical trials, increases their understanding of the information compared to conventional written information, in real (not simulated) conditions.

Conditions

  • Comprehension

Interventions

OTHER

readability improvement and good practice redaction

improvement using Flesch readability index and good practice in redaction of informed consent documents.

OTHER

Control

information based on the classic informed consent document

Sponsors & Collaborators

  • Clinical Research Center of Grenoble

    collaborator UNKNOWN
  • Clinical Research Center of Strasbourg

    collaborator UNKNOWN
  • Hôpital Necker-Enfants Malades

    collaborator OTHER
  • Clinical Research Center of Lyon

    collaborator UNKNOWN
  • Clinical Research Center of Bichat, Paris

    collaborator UNKNOWN
  • Clinical Research Center of Saint-Etienne

    collaborator UNKNOWN
  • Clinical Research Center - biotherapy center of Saint-Louis, Paris

    collaborator UNKNOWN
  • Clinical Research Center of Clermont-Ferrand

    collaborator UNKNOWN
  • Clinical Research Center of Reunion island

    collaborator UNKNOWN
  • Clinical Research Center - Biotherapy center of Nantes

    collaborator UNKNOWN
  • CIC 1417 Cochin-Pasteur

    collaborator OTHER
  • Pharmacology unit of Créteil

    collaborator UNKNOWN
  • Clinical Research Center, Toulouse

    collaborator OTHER
  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Jean-Luc CRACOWSKI, MD · Clinical Research Center Grenoble France

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-03-31
Completion
2014-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908557 on ClinicalTrials.gov